---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263684"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:41:25.407272+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q3 2025 net income $15.9M; vopimetostat mPFS 7.2 mo in pancreatic; cash runway into 2028

## Summary
- Net income $15.9M ($0.14 basic EPS) vs net loss $29.2M in Q3 2024; nine-month net loss $62.8M.
- Collaboration revenue $53.8M (Q3 2024: $11.6M) as Gilead collaboration truncated; all deferred revenue recognized.
- Vopimetostat in 2L MTAP-del pancreatic cancer showed median PFS 7.2 months; 49% ORR and mPFS 9.1 mo in histology-selective cohort.
- October 2025 financing raised $225M gross ($212M net); cash, equivalents and marketables $152.8M as of Sept 30, extending runway into 2028.
- TNG456 granted Orphan Drug Designation for malignant glioma; pivotal pancreatic study for vopimetostat anticipated to start 2026.

## SEC filing metadata
- accession: 0001193125-25-263684
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312525263684/0001193125-25-263684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312525263684/tngx-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263684
- JSON: https://secwatch.observer/filing/0001193125-25-263684.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.